Cargando…

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis

OBJECTIVE: To compare the rate of relapse as a function of antipsychotic treatment (monotherapy vs. polypharmacy) in schizophrenic patients over a 2-year period. METHODS: Using data from a multicenter cohort study conducted in France, we performed a propensity-adjusted analysis to examine the associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Millier, Aurelie, Sarlon, Emmanuelle, Azorin, Jean-Michel, Boyer, Laurent, Aballea, Samuel, Auquier, Pascal, Toumi, Mondher
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045883/ https://www.ncbi.nlm.nih.gov/pubmed/21314943 http://dx.doi.org/10.1186/1471-244X-11-24

Ejemplares similares

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
por: Azaiez, Chiraz, et al.
Publicado: (2018)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Evaluation of patients on sertindole treatment after failure of other antipsychotics: A retrospective analysis
por: Azorin, Jean-Michel, et al.
Publicado: (2008)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data
por: Rahhali, Nora, et al.
Publicado: (2015)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
por: Thokagevistk, Katia, et al.
Publicado: (2016)

Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
por: Hanna, Eve, et al.
Publicado: (2016)

Gene therapies development: slow progress and promising prospect
por: Hanna, Eve, et al.
Publicado: (2017)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics
por: Ko, You-Kyung, et al.
Publicado: (2013)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Evolution of symptoms with antipsychotic treatment in schizophrenic outpatients in Greece: the GRACE Study
por: Karadima, Dimitra, et al.
Publicado: (2010)

Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs
por: Dogan, Halef Okan, et al.
Publicado: (2018)

Effect of antipsychotic drugs and orthostatic hypotension on the risk of falling in schizophrenic patients
por: Ferinauli, Ferinauli, et al.
Publicado: (2021)

Cultural Variations in Public Beliefs about Mental Disorders: A Comparison between Tunisia and Germany
por: Angermeyer, Matthias C., et al.
Publicado: (2020)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
por: Suda, Akira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b9p81dvn08qbm4i6k1eauj49nq